Saluda Medical Announces Successful Financing Round
Saluda Medical, Inc., a company dedicated to developing innovative treatments for chronic neurological conditions, has successfully closed a significant financing round totaling $100 million. This funding round primarily aims to accelerate the commercialization of their flagship product, the Evoke System, which utilizes an advanced, closed-loop, dose-control neuromodulation platform tailored for chronic pain management.
Investment and Strategic Support
The financing was spearheaded by the existing investor Redmile Group, who played a pivotal role in this round of funding. Other notable participants included Wellington Management, TPG Life Sciences Innovation, Fidelity Management & Research Company, Action Potential Venture Capital, and funds managed by T. Rowe Price Associates, Inc. Newcomer Piper Heartland Healthcare Capital contributed to this funding effort as well, showcasing a robust interest in advancing neuromodulation technology.
Utilization of Funds
The newly acquired capital will primarily be utilized to further advance the commercialization efforts of the Evoke System. The Evoke System stands out as the first-of-its-kind physiologic closed-loop spinal cord stimulation (SCS) technology designed specifically to manage chronic pain effectively and adaptively.
The Evoke System: A Revolutionary Solution
This state-of-the-art system is intended for individuals suffering from chronic pain, a condition affecting approximately 20% of the global population. Within the United States, about 67 million people experience chronic pain, highlighting the urgent need for effective solutions. While spinal cord stimulation is already recognized as an effective therapy for chronic pain, the Evoke System uniquely measures neural responses to stimulation, allowing for automatic adjustments in therapy. This capability helps to ensure that the therapy remains aligned with the patient’s specific neural activation levels, thereby maximizing treatment efficacy and consistency.
About Saluda Medical
Saluda Medical is on a mission to transform the landscape of pain management through its novel neuromodulation solutions. Their closed-loop, dose-control platform is engineered to provide real-time feedback on neural responses, enabling dynamic adjustments to therapy as needed. This approach aims to optimize treatment outcomes while significantly minimizing the burdens on both patients and healthcare providers.
Clinical Evidence Supporting Evoke
The Evoke System has been rigorously tested, with 12-month results from the EVOKE study published in The Lancet Neurology. Further findings demonstrating sustained pain relief were published in JAMA Neurology and Regional Anesthesia and Pain Medicine, reflecting the device's promising outcomes over extended periods. These publications provide compelling evidence of the Evoke System's potential to alleviate chronic pain consistently.
Contact Information for Investors
Investors seeking additional information about Saluda Medical and its innovative product offerings can reach out to Brian Johnston or Sam Bentzinger for inquiries. The company values transparency and encourages interested parties to connect directly for further details.
Frequently Asked Questions
What is Saluda Medical known for?
Saluda Medical specializes in developing advanced treatments for chronic neurological conditions using a unique neuromodulation platform.
What is the Evoke System?
The Evoke System is a closed-loop spinal cord stimulation device designed to manage chronic pain by adjusting therapy based on real-time neural feedback.
Who led the recent financing round for Saluda Medical?
The financing round was led by Redmile Group, with participation from various esteemed investors in the medical field.
What will the financing be used for?
The funds will focus on advancing the commercialization of the Evoke System, enhancing its availability for patients in need.
How prevalent is chronic pain globally?
Chronic pain affects approximately 20% of the global population, which equates to around 67 million individuals in the United States alone.
